Back to Journals » ImmunoTargets and Therapy » Volume 5

Immunotherapy for tuberculosis: future prospects

Authors Abate G, Hoft D

Received 24 November 2015

Accepted for publication 27 January 2016

Published 20 April 2016 Volume 2016:5 Pages 37—45


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Federico Perche

Peer reviewer comments 5

Editor who approved publication: Professor Michael Shurin

Getahun Abate,1 Daniel F Hoft1,2

1Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, 2Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO, USA

Abstract: Tuberculosis (TB) is still a major global health problem. A third of the world's population is infected with Mycobacterium tuberculosis. Only ~10% of infected individuals develop TB but there are 9 million TB cases with 1.5 million deaths annually. The standard prophylactic treatment regimens for latent TB infection take 3–9 months, and new cases of TB require at least 6 months of treatment with multiple drugs. The management of latent TB infection and TB has become more challenging because of the spread of multidrug-resistant and extremely drug-resistant TB. Intensified efforts to find new TB drugs and immunotherapies are needed. Immunotherapies could modulate the immune system in patients with latent TB infection or active disease, enabling better control of M. tuberculosis replication. This review describes several types of potential immunotherapies with a focus on those which have been tested in humans.

Keywords: tuberculosis, HDT, immunotherapy, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Breast cancer characteristics in very young Egyptian women ≤35 years

Farouk O, Ebrahim MA, Senbel A, Emarah Z, Abozeed W, Seisa MO , Mackisack S, Abdel Jalil S, Abdelhady S

Breast Cancer: Targets and Therapy 2016, 8:53-58

Published Date: 5 April 2016

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Application of liposomal technologies for delivery of platinum analogs in oncology

Liu D, He C, Wang AZ, Lin W

International Journal of Nanomedicine 2013, 8:3309-3319

Published Date: 26 August 2013

Breakthrough cancer pain – still a challenge

Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, Cruz JJ, Galvez R, Mañas A, Zaragozá F

Journal of Pain Research 2012, 5:559-566

Published Date: 19 November 2012

Use of electronic medical records in oncology outcomes research

Gena Kanas, Libby Morimoto, Fionna Mowat, et al

ClinicoEconomics and Outcomes Research 2010, 2:1-14

Published Date: 24 February 2010